Axsome Therapeutics, Inc.
NASDAQ:AXSMBiotechnology
+$0.25 today
- Market cap
- $7.05B
- Beta
- 0.60
- P/E (TTM)
- -68.6
- EPS (TTM)
- -$3.68
Volume 0.74M
Average 0.72M
AXSM Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
Axsome Therapeutics, Inc.NASDAQ: AXSM
Revenue · Q2 FY2026 · quarter ended Jun 2026
Revenue grows, but more slowly than its trailing trend
Q2 FY2026 revenue of $218.38M rose 45.5% year over year, behind the +56.9% change in trailing-twelve-month revenue. Sequentially, it rose 14.2% from the prior quarter. Over 3 fiscal years it compounded at +133.7% a year.
Context
- Revenue increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether revenue reaches the consensus estimate from 16 analysts of $954.09M (+49.4%) for the fiscal year ending Dec 2026, a slowdown from the +65.5% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $218.38M+14.2% QoQ
- Last fiscal yearDec 2025
- $638.5M+65.5% YoY
- LTMJun 2026
- $776.57M+56.9% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +45.5% | +45.7% | +0.2 pp |
| 1 year | +65.5% | +49.4% | -16.1 pp |
| 3-year CAGR | +133.7% | +47.7% | -86.0 pp |
| 5-year CAGR | +40.7% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
USD · from the income statement
- Latest · FY2025
- 638.5M USD
- Year-over-year change
- +65.5%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 638.5M | +65.5% |
| FY2024 | 2024-12-31 | 385.69M | +42.5% |
| FY2023 | 2023-12-31 | 270.6M | +440.8% |
| FY2022 | 2022-12-31 | 50.04M | — |
| FY2021 | 2021-12-31 | 0 | — |
Revenue vs competitors
How AXSM compares with its peers on the latest reported figures
- AXSM's LTM Jun 2026 revenue of $776.57M is the 4th highest of the 11 companies compared; the peer median is $1.8M.
- Its year-over-year change of +56.9% is the highest of 6, against a peer median of +13.5%.
- Over three fiscal years its annual growth of +133.7% compares with a peer median of +3.9%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Sep 2026 | $4.72B | +13.5% | +5.3% | |
| LTM Sep 2026 | $3.7B | +38.0% | +24.3% | |
| LTM Jun 2026 | $830.44M | +24.9% | +2.5% | |
| LTM Jun 2026 | $776.57M | +56.9% | +133.7% | |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | $20M | — | — |
| LTM Jun 2026 | $3.6M | — | — | |
| LTM Sep 2026 | $0 | -100.0% | — | |
DFTXDefinium Therapeutics, Inc. | LTM Sep 2026 | $0 | — | — |
| LTM Sep 2026 | $0 | -100.0% | -7.4% | |
| LTM Dec 2025 | $0 | — | — | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $0 | — | — |
| Peer median (excluding AXSM) | $1.8M | +13.5% | +3.9% | |
Competitors are the stored peer set for AXSM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 50.04M | 270.6M | 385.69M | 638.5M |
| Cost of Revenue | 0 | 5.2M | 26.07M | 33.3M | 47.48M |
| Gross Profit | 0 | 44.84M | 244.54M | 352.39M | 591.02M |
| Gross Margin | — | 89.6% | 90.4% | 91.4% | 92.6% |
| Research & Development | 58.06M | 57.95M | 97.94M | 187.08M | 183.28M |
| Selling, General & Admin | 66.65M | 159.25M | 323.12M | 411.36M | 570.6M |
| Operating Expenses | 124.71M | 224.64M | 476.36M | 632.95M | 760.25M |
| Depreciation & Amortization | 76K | 4.4M | 6.83M | 7.96M | 9.06M |
| EBITDA | (124.63M) | (175.4M) | (224.99M) | (272.6M) | (168.08M) |
| EBITDA Margin | — | -350.5% | -83.1% | -70.7% | -26.3% |
| Operating Income | (124.71M) | (179.8M) | (231.83M) | (280.56M) | (169.24M) |
| Operating Margin | — | -359.3% | -85.7% | -72.7% | -26.5% |
| Interest Income | 0 | 0 | 0 | 0 | 9.37M |
| Interest Expense | 5.7M | 7.34M | 6.45M | 6.57M | 6.56M |
| Other Income / Expenses | (5.7M) | (7.34M) | (6.45M) | (6.57M) | (14.47M) |
| Income Before Tax | (130.4M) | (187.13M) | (238.28M) | (287.13M) | (183.7M) |
| Pre-Tax Margin | — | -374.0% | -88.1% | -74.4% | -28.8% |
| Income Tax Expense | 0 | 0 | 960K | 85K | (530K) |
| Net Income | (130.4M) | (187.13M) | (239.24M) | (287.22M) | (183.17M) |
| Net Margin | — | -374.0% | -88.4% | -74.5% | -28.7% |
| EPS (Basic) | (3.47) | (4.60) | (5.27) | (5.99) | (3.68) |
| EPS (Diluted) | (3.47) | (4.60) | (5.27) | (5.99) | (3.68) |
| Weighted Avg Shares | 37.62M | 40.66M | 45.43M | 47.91M | 49.75M |
| Weighted Avg Shares (Diluted) | 37.62M | 40.66M | 45.43M | 47.91M | 49.75M |
Axsome Therapeutics, Inc.
NASDAQ:AXSM
Intrinsic Alpha fair value
Locked
Current Price
$134.00
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.